Interpreting Key Trials
Angiotensin-receptor blockers in heart failure
Evidence from the CHARM trial
Shyam Bhakta, MD and Mark E. Dunlap, MD
Cleveland Clinic Journal of Medicine August 2004, 71 (8) 665-673;
Shyam Bhakta
Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland
Mark E. Dunlap
Director, Heart Failure Program and Associate Chief, Cardiology Section, Louis B. Stokes Veterans Affairs Medical Center; Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University, Cleveland; national leader, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial

Article Information
vol. 71 no. 8 665-673
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online August 1, 2004.
Copyright & Usage
Copyright © 2004 The Cleveland Clinic Foundation. All Rights Reserved.
In this issue
Cleveland Clinic Journal of Medicine
Vol. 71, Issue 8
1 Aug 2004
Angiotensin-receptor blockers in heart failure
Shyam Bhakta, Mark E. Dunlap
Cleveland Clinic Journal of Medicine Aug 2004, 71 (8) 665-673;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.





